488 related articles for article (PubMed ID: 11084478)
1. [Management of intractable cancer pain: from intrathecal morphine to cell allograft].
Lazorthes Y; Sallerin B; Verdie JC; Sol JC; Duplan H; Tkaczuk J; Tafani M; Bastide R; Bes JC
Neurochirurgie; 2000 Nov; 46(5):454-65. PubMed ID: 11084478
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids.
Mercadante S; Intravaia G; Villari P; Ferrera P; Riina S; David F; Mangione S
Clin J Pain; 2007; 23(9):793-8. PubMed ID: 18075407
[TBL] [Abstract][Full Text] [Related]
3. Intrathecal xenogeneic chromaffin cell grafts reduce nociceptive behavior in a rodent tonic pain model.
Sol JC; Sallerin B; Larrue S; Li RY; Jozan S; Tortosa F; Mascott C; Carraoue F; Tafani M; Lazorthes Y
Exp Neurol; 2004 Apr; 186(2):198-211. PubMed ID: 15026256
[TBL] [Abstract][Full Text] [Related]
4. Drug-related side effects of long-term intrathecal morphine therapy.
Ruan X
Pain Physician; 2007 Mar; 10(2):357-66. PubMed ID: 17387357
[TBL] [Abstract][Full Text] [Related]
5. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
6. [Intrathecal morphine treatment in advanced cancer pain patients].
Hattori S; Sano H; Tanaka K; Yokota M
Masui; 2009 Nov; 58(11):1384-92. PubMed ID: 19928505
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal drug delivery for the management of cancer pain: a multidisciplinary consensus of best clinical practices.
Stearns L; Boortz-Marx R; Du Pen S; Friehs G; Gordon M; Halyard M; Herbst L; Kiser J
J Support Oncol; 2005; 3(6):399-408. PubMed ID: 16350425
[TBL] [Abstract][Full Text] [Related]
8. [Nociceptive cancer pain in adult patients: statement about guidelines related to the use of antinociceptive medicine].
Binhas M; Krakowski I; Marty J
Ann Fr Anesth Reanim; 2007 Jun; 26(6):502-15. PubMed ID: 17560755
[TBL] [Abstract][Full Text] [Related]
9. Continuous intrathecal morphine infusion in patients with vertebral fractures due to osteoporosis.
Shaladi A; Saltari MR; Piva B; Crestani F; Tartari S; Pinato P; Micheletto G; Dall'Ara R
Clin J Pain; 2007; 23(6):511-7. PubMed ID: 17575491
[TBL] [Abstract][Full Text] [Related]
10. Outcome of intrathecal opioids in chronic non-cancer pain.
Roberts LJ; Finch PM; Goucke CR; Price LM
Eur J Pain; 2001; 5(4):353-61. PubMed ID: 11743701
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain.
Deer TR; Smith HS; Burton AW; Pope JE; Doleys DM; Levy RM; Staats PS; Wallace MS; Webster LR; Rauck RL; Cousins M;
Pain Physician; 2011; 14(3):E283-312. PubMed ID: 21587338
[TBL] [Abstract][Full Text] [Related]
12. Human chromaffin cell graft into the CSF for cancer pain management: a prospective phase II clinical study.
Lazorthes Y; Sagen J; Sallerin B; Tkaczuk J; Duplan H; Sol JC; Tafani M; Bès JC
Pain; 2000 Jul; 87(1):19-32. PubMed ID: 10863042
[TBL] [Abstract][Full Text] [Related]
13. Ziconotide: new drug. Limited analgesic efficacy, too many adverse effects.
Prescrire Int; 2008 Oct; 17(97):179-82. PubMed ID: 19530373
[TBL] [Abstract][Full Text] [Related]
14. [Clinical perspectives of xenografts: encapsulated chromaffin cells and pain].
Bès JC; Lazorthes Y; Sol JC; Tkaczuk J; Sallerin B
Pathol Biol (Paris); 2000 May; 48(4):365-7. PubMed ID: 10868399
[TBL] [Abstract][Full Text] [Related]
15. [Intrathecal administration of morphine and bupivacaine in the treatment of severe pain in chronic pancreatitis].
Verheijen R; Slappendel R; Jansen JB; Crul BJ; van Dongen RT
Ned Tijdschr Geneeskd; 1996 Jul; 140(27):1410-2. PubMed ID: 8766685
[TBL] [Abstract][Full Text] [Related]
16. Loss of intrathecal morphine analgesia in terminal cancer patients is associated with high levels of excitatory amino acids in the CSF.
Wong CS; Chang YC; Yeh CC; Huang GS; Cherng CH
Can J Anaesth; 2002; 49(6):561-5. PubMed ID: 12067866
[TBL] [Abstract][Full Text] [Related]
17. [Continuous intrathecal opiate therapy with a portable drug pump in cancer pain].
Motsch J; Bleser W; Ismaily AJ; Distler L
Anasth Intensivther Notfallmed; 1988 Oct; 23(5):271-5. PubMed ID: 2907271
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of severe cancer pain via spinal catheters].
Andersen JS; Markers PI; Valentin N
Ugeskr Laeger; 1996 Nov; 158(46):6613-6. PubMed ID: 8966828
[TBL] [Abstract][Full Text] [Related]
19. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
20. Median arcuate ligament syndrome--a novel treatment using an intrathecal morphine pump to relieve intractable visceral pain.
Guttman OT; Rosenblatt MA; Mims T
Pain Pract; 2008; 8(2):133-7. PubMed ID: 18194349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
